AAS
BCRX icon

Avantax Advisory Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Avantax Advisory Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25,000
Closed -$86K – 966
2020
Q3 		$86K Buy
+25,000
New +$107K ﹤0.01% 1313

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Avantax Advisory Services's BCRX Position: Q4 2020 in Review

Avantax Advisory Services sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2020, closing a stake of 25,000 shares — an estimated $86K sold.

Avantax Advisory Services first reported a position in BCRX in Q3 2020 and held it in 1 quarter. The position peaked at $86K in Q3 2020. 177 funds tracked by Wall St. Rank hold BCRX as of Q4 2020.

  • Avantax Advisory Services reported no remaining BioCryst Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Avantax Advisory Services sold 25,000 BioCryst Pharmaceuticals shares in Q4 2020, an estimated $86K.
  • Avantax Advisory Services first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Avantax Advisory Services's BioCryst Pharmaceuticals position peaked at $86K in Q3 2020.
  • 177 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2020.

Based on Avantax Advisory Services's 13F filing for Q4 2020, filed 22 Jan 2021.